PD-1/PD-L1 immune checkpoint inhibitors such as pembrolizumab and nivolumab revealed a strong response and improvement in overall survival in various tumor entities such as metastatic melanoma [11], non-small-cell lung cancer (NSCLC) and head and neck tumors [12]. This evidence concerns the gene CD274 and neoplasm.